Protara Therapeutics (TARA) Common Equity (2013 - 2026)

Protara Therapeutics' Common Equity history runs 14 years deep, the most recent figure standing at $181.2 million for Q1 2026.

• In Q1 2026, Common Equity rose 14.34% year-over-year to $181.2 million; the TTM figure through Mar 2026 stood at $181.2 million (up 14.34% YoY), while the FY2025 annual figure was $196.4 million, up 17.52% from the prior year.
• Common Equity was $181.2 million for Q1 2026 at Protara Therapeutics, down from $196.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $196.4 million in Q4 2025 to a low of $58.4 million in Q1 2024.
• Historically, Common Equity has averaged $122.1 million across 5 years, with a median of $132.3 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Common Equity slumped 44.71% in 2023, then soared 171.35% in 2025.
• A 5-year view of Common Equity shows it stood at $102.1 million in 2022, then sank by 33.07% to $68.3 million in 2023, then soared by 144.63% to $167.1 million in 2024, then advanced by 17.52% to $196.4 million in 2025, then fell by 7.74% to $181.2 million in 2026.
• The last three Common Equity figures came in at $181.2 million (Q1 2026), $196.4 million (Q4 2025), and $132.3 million (Q3 2025), per Business Quant data.